Archive | 2017 Rayno Tools and Diagnostics Portfolio

The Rayno Tools and Diagnostics Portfolio is on hold pending Q1 2017 earnings analysis. We are still in a bear market. Large caps like ThermoFisher (TMO) and Idexx Labs (IDXX) are among the safe plays but growth stocks such as Illumina (ILMN) have bottomed. New picks lie ahead as there are many good opportunities. We did add Hologic (HOLX) as a buy at $40 on December 20, 2016.

Rayno Life Science Portfolios: AMGN,CLVS,ILMN,RGEN,TMO…Update 3/18

March 18-Stealth Rally With A Tempered Tape In Biotech NASDAQ up 0.92% Biotech stocks lagged the surprising FED rally today maybe because money was moving to other sectors.This bears close watching because only this week biotech stocks hit a new high.Money may be moving to lagging sectors like energy up 2.92% today. Nonetheless healthcare remained […]

Continue Reading 0

Rayno Life Sciences DX and Tools Update: 2015 Q1 Winners ALR,FMI,HOLX

Diagnostic Stocks rally with NASDAQ and Small Caps –IWM Up 1.66% Life Science Tools and Diagnostics stocks are a tad off their one year highs hit by dollar strength and disappointing revenue growth in some cases. Sequencing stocks were big winners but sold off after the JPMorgan Conference. Nonetheless the sector is attractive longer term […]

Continue Reading 0

Rayno Dx and Tools: Update EXAS

Valuation Does Matter If Revenue Growth Slows Last week we posted a YTD summary of our diagnostics and tools focus stocks. Three stocks that are up over one year but have been weak in 2015. We said that revenue guidance and technicals will be important for: Exact Sciences (EXAS), Genomic Health (GHDX) and Neogen (NEOG). […]

Continue Reading 0

Rayno Dx and Tools: 2015 Q1 Mid Quarter Update-FMI, CSII, HOLX, ALR

Bullish Trend Continues for Mid-Cap Growth Stocks The Life Science Tools and Clinical Diagnostics sector kept pace with major life science ETF performance. Major  ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%. We will provide an update of our  Clinical Diagnostics portfolio after all earnings reports are in. […]

Continue Reading 0

Rayno Dx and Tools Portfolio: CSII HOLX ILMN TMO Stellar Performers

Solid  earnings reports-All of Our Picks Are Strong Holds But Strong Dollar a Factor in 2105 Cardiovascular Systems (CSII) Stock Soars 15% On Strong Revenues Interventional treatments for cardiovascular disease Q2 Revenues soared 38% to $44.7M compared to previous fiscal Q2 2014. Fiscal Q2 2105 loss was $5.3M or (0.17) per share. Hologic (HOLX) Beats […]

Continue Reading 0

Rayno Small Cap Picks: FCSC, PACB Update-1

Update 1/15 Fibrocell Science has moved another 3.5% probably related to recent moves of Intrexon (XON) up 3% today. Both FCSC and XON have Third Security LLC as major holder, PACB is down 4.78% on profit taking. Biotech is a tad weak today after 3 days of the JPMorgan Conference; even the MO stocks are […]

Continue Reading 0

JPMorgan Healthcare Conference Notes #1: Sequencing Picks Romp-FMI

Sequencing Remains Hot-Roche (RHHBY) Deal With Foundation Medicine (FMI) Worth $1.1B Targeted Oncology Therapy-Molecular information from pathways and biomarkers e.g. PDL-1 RNA based immunotherapy test Continuous  monitoring of tumor specific information and molecular alterations All of our sequencing picks were up  1/12 on Roche equity deal to support oncology with personalized medicine development. Two other […]

Continue Reading 0

Happy New Year 2015!

Wishing you all a Happy and Prosperous New Year! Biotech stocks were up 47% in 2014. In 2014 the first quarter was the most volatile. Sign up now to receive all of our market and portfolio updates. In December we posted updates on our Rayno Life Science Portfolios: Rayno Diagnostics and Tools Part 2: Rayno […]

Continue Reading 0

Rayno Dx and Tools 2014 Performance YTD: ABAX EXAS ILMN PACB SQNM

Many Big Winners Are Among  Rayno Diagnostics and Tools Stocks in 2014 Abaxis (ABAX) up 46%  A major “Point of Care” (POC) Dx Player in veterinary and human markets. Exact Sciences (EXAS) up 135%  An emerging Dx player with non-invasive, DNA based test for colon cancer. Illumina Inc. (ILMN) up 68%  Leading provider of DNA […]

Continue Reading 0

Rayno Life Science: Market Update 11/26… Stocks Cruise To New Highs

NASDAQ leads -up 0.6% to 4787 The October correction of ~7% was a “headfake” as macro events scared many investor away Technology and Healthcare Stocks Lead The Way The healthcare SPDR (XLV) is up 24.5% YTD and the technology SPDR (XLK) is up 18% YTD. Biotech stocks are at new highs with all major ETFs […]

Continue Reading 0